Your browser is no longer supported. Please, upgrade your browser.
iShares Evolved U.S. Innovative Healthcare ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week2.88%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-0.87%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-2.18%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y6.35%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year22.44%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range26.98 - 35.15 Perf YTD1.40%
Dividend0.91 P/FCF- EPS past 5Y- ROI- 52W High-6.29% Beta-
Dividend %2.77% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low22.08% ATR0.45
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)57.80 Volatility0.88% 1.37%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.25 Prev Close32.81
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume7.11K Price32.94
Recom- SMA202.35% SMA500.16% SMA2005.24% Volume793 Change0.39%
Nov-19-20 04:00AM  
Oct-16-19 10:05AM  
Aug-27-19 10:05AM  
Jul-17-19 10:50AM  
Apr-17-19 10:35AM  
Mar-12-19 11:05AM  
Jan-23-19 10:59AM  
Jan-04-19 10:01AM  
Nov-26-18 11:15AM  
The investment seeks to provide access to U.S. companies with innovative healthcare exposure, as classified using a proprietary classification system. The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.